Shionogi Chief Defends Xocova Data, Eager to Prove Benefits in Clinical Settings

November 25, 2022
Shionogi President Isao Teshirogi (left) Shionogi President Isao Teshirogi on November 24 expressed the company’s unflinching confidence about data obtained from its newly approved COVID-19 pill Xocova (ensitrelvir), brushing aside skepticism around what some see as marginal benefits offered by...read more